Terms: = Liver cancer AND PDCD1, CD279, PD-1, PD1, SLEB2, hPD-1, hPD-l, hSLE1 AND Clinical Outcome
27 results:
1. Tumor cell-derived LC3B
Chen YQ; Man ZS; Zheng L; Zhang Y; Zhao CW; Ma YT; Zhou J; Wang P; Yu Y; Gu F; Niu GP
Clin Immunol; 2024 Apr; 261():109925. PubMed ID: 38310993
[TBL] [Abstract] [Full Text] [Related]
2. APOBEC3C is a novel target for the immune treatment of lower-grade gliomas.
Zhao S; Li Y; Xu J; Shen L
Neurol Res; 2024 Mar; 46(3):227-242. PubMed ID: 38007705
[TBL] [Abstract] [Full Text] [Related]
3. Comparison of Baseline
Wu M; Wang Y; Yang Q; Wang X; Yang X; Xing H; Sang X; Li X; Zhao H; Huo L
J Nucl Med; 2023 Oct; 64(10):1532-1539. PubMed ID: 37500263
[TBL] [Abstract] [Full Text] [Related]
4. Cholesterol Efflux Drives the Generation of Immunosuppressive Macrophages to Promote the Progression of Human Hepatocellular Carcinoma.
Li Z; Wang Y; Xing R; Zeng H; Yu XJ; Zhang YJ; Xu J; Zheng L
Cancer Immunol Res; 2023 Oct; 11(10):1400-1413. PubMed ID: 37467346
[TBL] [Abstract] [Full Text] [Related]
5. clinical outcomes of lenvatinib plus transarterial chemoembolization with or without programmed death receptor-1 inhibitors in unresectable hepatocellular carcinoma.
Wang YY; Yang X; Wang YC; Long JY; Sun HS; Li YR; Xun ZY; Zhang N; Xue JN; Ning C; Zhang JW; Zhu CP; Zhang LH; Yang XB; Zhao HT
World J Gastroenterol; 2023 Mar; 29(10):1614-1626. PubMed ID: 36970591
[TBL] [Abstract] [Full Text] [Related]
6. H4-methylation regulators mediated epitranscriptome patterns and tumor microenvironment infiltration characterization in hepatocellular carcinoma.
Yu L; Ji T; Liao W; Xu Y; Fang Y; Zhu Q; Nie J; Yang D
Clin Epigenetics; 2023 Mar; 15(1):43. PubMed ID: 36932439
[TBL] [Abstract] [Full Text] [Related]
7. Overweight/obesity-related transcriptomic signature as a correlate of clinical outcome, immune microenvironment, and treatment response in hepatocellular carcinoma.
Feng NN; Du XY; Zhang YS; Jiao ZK; Wu XH; Yang BM
Front Endocrinol (Lausanne); 2022; 13():1061091. PubMed ID: 36714595
[TBL] [Abstract] [Full Text] [Related]
8. The use of medical cannabis concomitantly with immune checkpoint inhibitors in non-small cell lung cancer: A sigh of relief?
Waissengrin B; Leshem Y; Taya M; Meiri D; Merimsky O; Shamai S; Wolf I; Rubinek T
Eur J Cancer; 2023 Feb; 180():52-61. PubMed ID: 36535195
[TBL] [Abstract] [Full Text] [Related]
9. Integrated transcriptomics unravels implications of glycosylation-regulating signature in diagnosis, prognosis and therapeutic benefits of hepatocellular carcinoma.
Tang H; Yang Q; Tang Q; Li X; Ding W; Chen W
Comput Biol Med; 2022 Sep; 148():105886. PubMed ID: 35973372
[TBL] [Abstract] [Full Text] [Related]
10. Lenvatinib Plus Programmed Cell Death Protein-1 Inhibitor Beyond First-Line Systemic Therapy in Refractory Advanced Biliary Tract cancer: A Real-World Retrospective Study in China.
Shi C; Li Y; Yang C; Qiao L; Tang L; Zheng Y; Chen X; Qian Y; Yang J; Wu D; Xie F
Front Immunol; 2022; 13():946861. PubMed ID: 35967452
[TBL] [Abstract] [Full Text] [Related]
11. Association of hepatitis B virus DNA levels with overall survival for advanced hepatitis B virus-related hepatocellular carcinoma under immune checkpoint inhibitor therapy.
An M; Wang W; Zhang J; Till BG; Zhao L; Huang H; Yang Y; Li T; Han L; Zhang X; Qin P; Wang Y; Zhang M; Cui H; Gao Q; Wang Z
Cancer Immunol Immunother; 2023 Feb; 72(2):385-395. PubMed ID: 35907016
[TBL] [Abstract] [Full Text] [Related]
12. PD-L1 PET/CT Imaging with Radiolabeled Durvalumab in Patients with Advanced-Stage Non-Small Cell Lung cancer.
Smit J; Borm FJ; Niemeijer AN; Huisman MC; Hoekstra OS; Boellaard R; Oprea-Lager DE; Vugts DJ; van Dongen GAMS; de Wit-van der Veen BJ; Thunnissen E; Smit EF; de Langen AJ
J Nucl Med; 2022 May; 63(5):686-693. PubMed ID: 34385342
[TBL] [Abstract] [Full Text] [Related]
13. Pretreatment metastatic growth rate determines clinical outcome of advanced melanoma patients treated with anti-pd-1 antibodies: a multicenter cohort study.
Wagner NB; Lenders MM; Kühl K; Reinhardt L; André F; Dudda M; Ring N; Ebel C; Stäger R; Zellweger C; Lang R; Paar M; Gussek P; Richtig G; Stürmer SH; Kimeswenger S; Oellinger A; Forschner A; Leiter U; Weide B; Gassenmaier M; Schraag A; Klumpp B; Hoetzenecker W; Berking C; Richtig E; Ziemer M; Mangana J; Terheyden P; Loquai C; Nguyen VA; Gebhardt C; Meier F; Diem S; Cozzio A; Flatz L; Röcken M; Garbe C; Eigentler TK
J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 33986126
[TBL] [Abstract] [Full Text] [Related]
14. Cell-free DNA copy number variations predict efficacy of immune checkpoint inhibitor-based therapy in hepatobiliary cancers.
Yang X; Hu Y; Yang K; Wang D; Lin J; Long J; Xie F; Mao J; Bian J; Guan M; Pan J; Huo L; Hu K; Yang X; Mao Y; Sang X; Zhang J; Wang X; Zhang H; Zhao H
J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 33972389
[TBL] [Abstract] [Full Text] [Related]
15. Immunobiology and immunotherapy of HCC: spotlight on innate and innate-like immune cells.
Ruf B; Heinrich B; Greten TF
Cell Mol Immunol; 2021 Jan; 18(1):112-127. PubMed ID: 33235387
[TBL] [Abstract] [Full Text] [Related]
16. pd-1/PD-L1 expression profiles within intrahepatic cholangiocarcinoma predict clinical outcome.
Tian L; Ma J; Ma L; Zheng B; Liu L; Song D; Wang Y; Zhang Z; Gao Q; Song K; Wang X
World J Surg Oncol; 2020 Nov; 18(1):303. PubMed ID: 33228682
[TBL] [Abstract] [Full Text] [Related]
17. Heterogeneity of exhausted T cells in the tumor microenvironment is linked to patient survival following resection in hepatocellular carcinoma.
Liu F; Liu W; Sanin DE; Jia G; Tian M; Wang H; Zhu B; Lu Y; Qiao T; Wang X; Shi Y; Wu D
Oncoimmunology; 2020; 9(1):1746573. PubMed ID: 32426177
[TBL] [Abstract] [Full Text] [Related]
18.
Wong A; Callahan J; Keyaerts M; Neyns B; Mangana J; Aberle S; Herschtal A; Fullerton S; Milne D; Iravani A; McArthur GA; Hicks RJ
Cancer Imaging; 2020 May; 20(1):36. PubMed ID: 32408884
[TBL] [Abstract] [Full Text] [Related]
19. Tumor-infiltrating immune cells in hepatocellular carcinoma: Tregs is correlated with poor overall survival.
Yu S; Wang Y; Hou J; Li W; Wang X; Xiang L; Tan D; Wang W; Jiang L; Claret FX; Jiao M; Guo H
PLoS One; 2020; 15(4):e0231003. PubMed ID: 32240238
[TBL] [Abstract] [Full Text] [Related]
20. pd1
Ma J; Zheng B; Goswami S; Meng L; Zhang D; Cao C; Li T; Zhu F; Ma L; Zhang Z; Zhang S; Duan M; Chen Q; Gao Q; Zhang X
J Immunother Cancer; 2019 Nov; 7(1):331. PubMed ID: 31783783
[TBL] [Abstract] [Full Text] [Related]
[Next]
